Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 03 2019
Historique:
received: 05 09 2018
accepted: 28 02 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 6 10 2020
Statut: epublish

Résumé

Autosomal dominant polycystic kidney disease (ADPKD) is the most common renal genetic disorder, however it still lacks a cure. The discovery of new therapies heavily depends on understanding key signalling pathways that lead to ADPKD. The JAnus Kinase and Signal Transducers and Activators of Transcription (JAK/STAT) pathway is aberrantly activated and contributes to ADPKD pathogenesis via enhancing epithelial proliferation. Yet the mechanisms underlying the upregulation of JAK/STAT activity in this disease context is completely unknown. Here, we investigate the role of JAK2 in ADPKD using a murine model of ADPKD (Pkd1

Identifiants

pubmed: 30872773
doi: 10.1038/s41598-019-41106-3
pii: 10.1038/s41598-019-41106-3
pmc: PMC6418191
doi:

Substances chimiques

Piperidines 0
Pyrimidines 0
Pyrroles 0
TRPP Cation Channels 0
polycystic kidney disease 1 protein 0
tofacitinib 87LA6FU830
JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2
Curcumin IT942ZTH98

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4491

Références

Front Pharmacol. 2016 Nov 25;7:455
pubmed: 27932984
Lancet. 2018 Jun 23;391(10139):2477-2478
pubmed: 29908671
Biopharm Drug Dispos. 2018 Jun;39(6):289-297
pubmed: 29870054
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F479-F486
pubmed: 29513074
Altern Med Rev. 2009 Jun;14(2):141-53
pubmed: 19594223
JAKSTAT. 2012 Jul 1;1(3):216-8
pubmed: 24058776
Nat Rev Nephrol. 2013 Dec;9(12):694
pubmed: 24126592
Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202
pubmed: 21345977
J Clin Invest. 2018 Jul 2;128(7):2760-2762
pubmed: 29889100
Biochem Biophys Res Commun. 2006 Feb 10;340(2):359-68
pubmed: 16364242
Kidney Int. 2017 Mar;91(3):575-586
pubmed: 28104302
Dis Model Mech. 2016 Sep 1;9(9):1051-61
pubmed: 27491076
Curr Rheumatol Rep. 2018 May 30;20(7):42
pubmed: 29846814
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):646-51
pubmed: 11209060
J Immunol. 2003 Oct 1;171(7):3863-71
pubmed: 14500688
Matrix Biol. 2011 Sep;30(7-8):396-403
pubmed: 21864682
Diabetes. 2012 Sep;61(9):2280-8
pubmed: 22586581
Clin Exp Nephrol. 2018 Oct;22(5):1079-1087
pubmed: 29508162
Mol Biol Cell. 2011 Jun 1;22(11):1836-44
pubmed: 21471005
Hum Mol Genet. 2011 Nov 1;20(21):4143-54
pubmed: 21821671
Oncogene. 2003 Feb 13;22(6):894-905
pubmed: 12584569
BMC Nephrol. 2008 Aug 25;9:10
pubmed: 18721488
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7985-90
pubmed: 21518865
FEBS Open Bio. 2018 Jan 10;8(2):302-310
pubmed: 29435420
Acta Histochem. 2014 Oct;116(8):1331-6
pubmed: 25201116
Cell. 2002 Apr 19;109(2):157-68
pubmed: 12007403
J Biol Chem. 2014 Apr 18;289(16):11122-31
pubmed: 24599958
Anticancer Res. 2003 Jan-Feb;23(1A):363-98
pubmed: 12680238
Kidney Int. 2007 Jul;72(2):157-65
pubmed: 17396115
J Drug Target. 2016 Sep;24(8):694-702
pubmed: 26942997
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18067-72
pubmed: 22025716
Dev Cell. 2006 Jan;10(1):57-69
pubmed: 16399078
J Am Soc Nephrol. 2014 Aug;25(8):1737-48
pubmed: 24578126
Nephrol Dial Transplant. 2009 Aug;24(8):2458-63
pubmed: 19332866
J Biol Chem. 2003 May 2;278(18):16304-9
pubmed: 12595539
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Biochem Pharmacol. 2003 Dec 15;66(12):2323-31
pubmed: 14637190
Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F86-F96
pubmed: 29513071
Kidney Int. 2013 Jun;83(6):1099-108
pubmed: 23466997
Curr Med Chem. 2019;26(10):1806-1832
pubmed: 29589523
Mol Endocrinol. 2008 Aug;22(8):1825-41
pubmed: 18499741
JAKSTAT. 2013 Apr 1;2(2):e23650
pubmed: 24058808
J Cell Sci. 2018 Jul 6;131(13):
pubmed: 29848658
Hum Mol Genet. 2004 Dec 15;13(24):3069-77
pubmed: 15496422
J Am Soc Nephrol. 2015 Apr;26(4):888-95
pubmed: 25145933
Drug Discov Today Dis Mech. 2013 Dec 1;10(3-4):e113-e118
pubmed: 26523147
Blood. 2004 Jul 15;104(2):543-9
pubmed: 15044251

Auteurs

Foteini Patera (F)

Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom.

Alex Cudzich-Madry (A)

Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom.

Zhi Huang (Z)

Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom.

Maria Fragiadaki (M)

Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom. m.fragiadaki@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH